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• Consensus recommendations for managing bronchiectasis in 
Indigenous children and adults living in rural and remote 
regions were developed during a multidisciplinary workshop 
and were based on available systematic reviews.
• Successful diagnosis, management and prevention of 
bronchiectasis in Indigenous Australians requires access to 
comprehensive health care services, as well as improved 
housing, education and employment and reduced poverty 
levels.
• Diagnosis of bronchiectasis requires a chest high-resolution 
computed tomography scan. Children who have 
bronchiectasis symptoms but non-diagnostic scans are 
described as having chronic suppurative lung disease (CSLD), 
rather than bronchiectasis. Untreated CSLD may progress to 
bronchiectasis.
• Chronic wet cough (> 4 weeks) or recurrent wet cough 
(> 2 episodes/year) are important but often under-reported 
symptoms. Bronchiectasis is suspected when chronic cough is 
excessively prolonged (> 12 weeks) or if a chest radiographic 
abnormality persists despite appropriate therapy.
• Intensive treatment aims to improve symptom control and 
quality of life while preserving lung function and reducing acute 
exacerbation frequency.
• Antibiotics should be prescribed for acute infective episodes 
according to culture results of respiratory secretions, local 
susceptibility patterns and clinical severity. Patients not 
responding promptly to oral antibiotics should be hospitalised 
for more intensive treatment.
• Ongoing care requires regular primary health care and 
specialist review, including monitoring for complications 
and comorbidities. Corticosteroids, bronchodilators and 
mucoactive agents may be used in individual cases, but routine 
use is not recommended. Physiotherapy and exercise should 
be encouraged, nutrition optimised, environmental pollutants 
(including tobacco smoke) avoided, and immunisations 
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People with bronchiectasis have a more rapid decline in lung
function5 and a reduced life expectancy.6 In a Central Australian
study, hospitalised adults with bronchiectasis were shown to have
seriously impaired lung function (mean forced expiratory volume
in 1 second [FEV1], 36% of predicted value), despite their
relatively young age (23% were aged < 30 years).7 Furthermore,
the effects of bronchiectasis extend beyond the respiratory system8
— for example, it is an independent risk factor for atherosclerosis.9
There is evidence that effective management of bronchiectasis
improves wellbeing and reduces morbidity.10
Despite its relatively frequent occurrence in Indigenous people,
bronchiectasis is often undiagnosed. Moreover, its management
ranges from symptomatic treatment alone (in the belief that little
further can be done) to intensive management. In our previous
position statement we focused on bronchiectasis in Indigenous
children.4 Here we update the evidence and produce revised
consensus recommendations for the management of bronchiectasis
in both Indigenous adults and children from rural and remote
Australian communities. Our methods are explained in Box 1, a
summary of the evidence is presented in Box 2, and a concise list
of the recommendations appears in Box 3. Each recommendation
is discussed in more detail in the following text.
In drafting the recommendations, we recognised regional and
individual heterogeneity. Our latest position statement is not
intended for tertiary management. It is intended to provide a
framework for care and not to replace the clinical assessment and
judgement required for treating individual patients.
Objectives of our position statement
• To increase awareness of bronchiectasis in Indigenous children
and adults and improve detection rates and management.
• To develop a national consensus for managing bronchiectasis in
Indigenous children and adults living in rural and remote Austra-
lian communities.
Case definition of bronchiectasis and chronic 
suppurative lung disease
In the past, bronchiectasis was defined by postmortem histo-
pathology. Later, bronchograms became the gold standard for
Abbreviations
CF Cystic fibrosis
c-HRCT Chest high-resolution computed tomography
COPD Chronic obstructive pulmonary disease
CSLD Chronic suppurative lung disease
FEV1 Forced expiratory volume in 1 second
RCT Randomised controlled trialber 7 • 6 October 2008
POSITIO N STATEMENTdiagnosis before being replaced by chest high-resolution com-
puted tomography (c-HRCT) scans. Currently, bronchiectasis,
defined in terms of “irreversible dilatation of peripheral airways”, is
diagnosed by c-HRCT scans.16 The diagnostic radiographic criteria
are described elsewhere.16 In children, this radiology-based defini-
tion poses problems, for several reasons:15,17
• Extrapolating c-HRCT findings of bronchiectasis from adult
studies may be inappropriate for children, as morphology of the
airway and lungs changes with age;
• At least two c-HRCT scans (separated by an undefined period)
are required to confirm irreversible airway dilatation. For Indigen-
ous people from remote communities, this poses logistic difficul-
ties; and
• c-HRCT scans performed in different clinical states yield differ-
ent results.
Instead, paediatricians prefer to use the term chronic suppur-
ative lung disease (CSLD) to describe the condition of children
with symptoms of bronchiectasis (Box 4) but without confirmatory
c-HRCT findings. This assumes there is a continuum of potentially
reversible to irreversible airway injury following repeated infection
and that aggressive management of children with CSLD may
prevent bronchiectasis.15 The management of CSLD and bron-
chiectasis is the same. In contrast, adults with chronic cough and
sputum production without evidence of bronchiectasis on c-HRCT
scan may have chronic obstructive pulmonary disease (COPD) (if
airflow obstruction is demonstrated on spirometry) or chronic
bronchitis.
Recommendation 1
1a. CSLD describes respiratory symptoms and signs (Box 4) in
children without radiographic features of bronchiectasis.
1b. Chest HRCT scans are needed to confirm bronchiectasis as
a diagnosis.
Agreement level: A+, 86%; A, 14%
Grade: not applicable; evidence level: cohort studies
Investigations
Radiology
Plain chest x-rays are insensitive for diagnosing bronchiectasis.
Chest HRCT scans are performed when radiographic changes
of pneumonia persist18 despite adequate treatment or when
symptoms suggest bronchiectasis (Box 4). In children, c-HRCT
scans should only be conducted after specialist review, in view
of the frequent need for anaesthesia and the greater relative
radiation dose.
Recommendation 2
Patients with symptoms or signs of bronchiectasis need a c-
HRCT scan to confirm the diagnosis and to assess the severity
and extent of disease. Specialist advice is required before
ordering scans for children.
Agreement level: A+, 95%; A, 2.5%; A–, 2.5%
Grade: moderate; evidence level: cohort studies
Aetiology
Patients with bronchiectasis are investigated for possible aetiology
(Box 4), as there is evidence that this can influence management
and severity.19 However, even with extensive investigation, a cause
is often not found.20 In an Australian study of non-Indigenous
adults with newly diagnosed bronchiectasis,20 a specific cause was
identified in only 27/103 patients (26%). In another study, 8/65
Indigenous children with bronchiectasis (12%) had an underlying
contributing factor.3
1 Methods
The consensus group comprised 37 representatives from Aboriginal-
controlled community health organisations, remote health services, 
medical schools, research institutes and primary, secondary and 
tertiary health centres. Collectively, the group possessed expertise in 
Indigenous primary health care; paediatric and adult respiratory 
medicine; microbiology; paediatric and adult infectious diseases; 
tobacco control; rural and remote health; and public health.
One of the authors (A BC) performed an updated search (from a 
previous search in March 20068) of the PubMed and Cochrane Central 
Library databases using the text-words “bronchiectasis” or 
“suppurative lung disease” and “controlled trials”. Only full articles 
published in English were retrieved. Recommendations were formed 
based on the quality of supporting evidence using the GRADE 
system:11
• High: further research is very unlikely to change our confidence in 
the estimate of effect;
• Moderate: further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the 
estimate;
• Low: further research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to change the 
estimate; or
• Very low: any estimate of effect is very uncertain.
As relative risk or estimate of effect size were available in very few of 
the articles, the decision to upgrade a recommendation was primarily 
based on the likelihood of whether further research would have an 
effect on the recommendation. The grade was assessed by three 
authors (A BC, K G, P J T). We used a modified Delphi process to 
reach consensus on the recommendations based on a similar model 
described by Vakil et al.12
Each recommendation was discussed during a 2-day workshop held in 
Darwin (24–25 Nov 2007). When disagreements occurred, the 
recommendation was rephrased by workshop attendees (n =22), and 
these were voted on by all in the consensus group (a panel of 
speakers and others with relevant expertise but who were unable to 
attend the workshop). The document was also circulated more widely, 
but only those who responded (see below) were included in the list.
Agreement with a statement (A+, A, or A–) by two-thirds (ie, 67%) of 
the group was defined a priori as consensus. For the final 
recommendation, a 6-point Likert scale was used: A+ = agree 
strongly; A = agree with minor reservation; A– = agree with major 
reservation; D– = disagree with major reservation; D = disagree with 
minor reservation; D+ = disagree strongly.
Consensus group members
Adelaide: Ral Antic,* Lloyd Einsiedel;† Alice Springs: Andrew White,† 
Stephen Brady,† Erik Tikoft,† Emma Tilley,† Carmel Hattch,* Paul 
Torzillo;† Brisbane: Scott Bell,* Keith Grimwood,† Patricia Valery,† 
Brent Masters;† Cairns: Graeme Maguire;† Darwin: Malcolm 
MacDonald,† Peter Morris,† Amanda Leach,† Keith Edwards,† 
Jonathan Carapetis,† Gabrielle McCallum,† Alan Ruben,† David 
Thomas,† Anne Chang,† Bart Currie,* Allen Cheng,* Jo Wright,* Annie 
Whybourne,* Louise Martin,* Paul Bauert,* Carolyn Maclennan,* 
Ngiare Brown;* Melbourne: Paul King,† Kim Mulholland,* Colin 
Robertson,* Sarath Ranganathan;* Perth: Deborah Lehman,† Lou 
Landau;* Sydney: Paul Torzillo,† Peter Van Asperen.*
* Voted on recommendations. † Attended workshop. ◆MJA • Volume 189 Number 7 • 6 October 2008 387
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2 Possible interventions for management of chronic suppurative lung disease (CSLD)
Evidence type/study Summary of results
Antimicrobials (by type)
General Cochrane review, other systematic review* Generally beneficial. See text
Macrolides†13 RCT and reviews*14 conducted over 2–6 
months
Exacerbations significantly reduced in treatment arm, with reduction in 
sputum and symptoms and PFT improvement in some patients14
Nebulised tobramycin*†‡ Double-blind crossover RCT in 30 patients with 
PsA, 6 months each
Length of hospital stay reduced in tobramycin arm, no change in QOL or 
PFT
Antimicrobials (by time) 
Short-term (< 1 month) Multiple cohort studies* General clinical improvement
Medium-term 
(1–11 months)
Cochrane review, other systematic reviews*14 Improvement with amoxycillin and macrolides (see above). Adults with 
PsA had reduced hospitalisation but no change in QOL*
Long-term 
( 12 months)
RCTs* Adults with PsA had reduced hospitalisation frequency and length of 
stay.* Reduced general disability in patients given tetracycline 
compared with placebo*
Anti-inflammatories
Oral NSAIDs§ Cochrane review* No RCTs
Inhaled indomethacin RCT in 25 adults, some with CSLD* Reduced sputum and improved dyspnoea score
Mucolytics
Bromhexine¶ Cochrane review* Studies only in acute phase
rhDNase Systematic review* Increased exacerbation rate and accelerated decline in FEV1
Airway clearance
Chest physiotherapy Cochrane review* Two small trials on bronchiectasis
Inhaled hyperosmolar 
agents
Cochrane review,* additional RCT 
(non-blinded) using 7% hypertonic saline*
Two small short-term studies on mannitol showed benefit with regard to 
QOL only
Asthma therapies
Inhaled corticosteroids** Cochrane review* and other RCTs (see text) No significant effect of ICSs in Cochrane review.* Additional RCTs 
showed some benefit. Reduced exacerbation rate only seen in patients 
with PsA.*
Oral corticosteroids†† Cochrane review* No RCTs
Anticholinergics†† Cochrane review* No RCTs
β2-Agonists†† Cochrane review* No RCTs
LTRAs†† Cochrane review* No RCTs
Physical training
Cochrane review* and RCT,* which was 
included in Cochrane database as an abstract‡‡
Pulmonary rehabilitation improves exercise tolerance; no additional 
advantage of simultaneous inspiratory muscle training
Oxygen (domiciliary) No data on use as sole therapy* Consider data from COPD studies showing benefit in survival*
Surgery§§ Cochrane review* No RCTs. Cohort studies suggest benefit in selected cases*
Vaccines
Pneumococcal 23¶¶ Cochrane review* No RCTs
Influenza Cochrane review* No RCTs
Acupuncture RCT* Improvement in QOL but not in sputum or 6-minute walking test
Model of follow-up
Nurse-led Cochrane review* No difference in exacerbations but increase in hospitalisations in nurse-
led care compared with doctor-led care***
COPD = chronic obstructive pulmonary disease. FEV1 = forced expiratory volume in 1 second. ICS = inhaled corticosteroid. LTRA = leukotriene receptor antagonist. 
NSAID = non-steroidal anti-inflammatory drug. QOL = quality of life. PFT = pulmonary function test. PsA = Pseudomonas aeruginosa. RCT = randomised controlled trial. 
rhDNase = recombinant human deoxyribonuclease.
* For references, see Chang et al.15 † Antimicrobial resistance is a concern. ‡ Nebulised tobramycin is poorly tolerated in some patients. § In a cohort study, indomethacin 
25 mg three times a day for 28 days reduced neutrophil chemotaxis, but there was no change in levels of sputum albumin, elastase or myeloperoxidase (see Chang et 
al15 for reference). ¶ Not universally available. ** Limited applicability in children (high-dose ICSs unsuitable for children, and children less likely to have PsA infections). 
†† No other data found by a single-reviewer search of PubMed and Cochrane Library databases in Oct 2007. ‡‡ The data in the abstract that was in the Cochrane review 
were different from the actual results in the article. §§ Reduction in exacerbation rate similar in medically treated group. For adverse events of surgery, see Chang et al.15 
¶¶ Advocated, as vaccines reduce respiratory infections. *** Increased health care cost implications.  ◆
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Initial triggers for bronchiectasis are unknown, but animal models
suggest that both inadequate mucous clearance and persistent
infection are necessary.21,22 Consistent with this hypothesis, recur-
rent, severe pneumonia is a risk factor for the development of
bronchiectasis in Indigenous Australian children.23 In a Central
Australian study, 20% of Indigenous children hospitalised with
lobar pneumonia had chronic respiratory illness at 12-month
follow-up (most commonly, CSLD).18
Severity
Bronchiectasis is assessed by symptoms and signs, radiology and
pulmonary function. Pulmonary function tests, like spirometry
(which typically shows an obstructive pattern), are performed at
each review. However, as a marker for disease severity, pulmon-
ary function tests are relatively insensitive, especially in young
children.3 With increasing age, FEV1 values in bronchiectasis
patients decline more rapidly and are used as a prognostic
marker.5,6 As pulmonary hypertension can complicate severe
bronchiectasis,8 an echocardiogram is recommended for all
adults and for children with advanced disease. Respiratory failure
can occur in advanced bronchiectasis, in which case oximetry,
arterial blood gas measurement and polysomnography are
required to assess the need for domiciliary oxygen or non-
invasive ventilatory support.
The most frequent respiratory pathogens in children with CSLD
and bronchiectasis are Haemophilus influenzae, Streptococcus pneu-
moniae, Moraxella catarrhalis and, occasionally, Staphylococcus
aureus.8 Adult patients with bronchiectasis are also subject to
infection with these pathogens, as well as Pseudomonas aeruginosa
(associated with advanced disease),8 Aspergillus and non-tubercu-
lous mycobacteria.24,25
Recommendation 3
Perform baseline investigations. These include:
• Culturing airway secretion;
• Spirometry (when aged > 6 years);
• Immune function tests (Box 4);
• Bronchoscopy (for foreign body, airway abnormality and
microbiological culture);
•  Echocardiogram in adults (on specialist recommendation in
children); and
• Other investigations (eg, sweat test, tests for tuberculosis,
barium swallow) may be necessary in selected patients.
Agreement level: A+, 84%; A, 5%; A–, 11%
Grade: moderate; evidence level: cohort studies
Management
Although there is no definitive evidence to support an early
treatment approach, it is generally accepted that patients who have
CSLD and are thus at risk of bronchiectasis will benefit from early
treatment. A longitudinal study has shown that patients with
3 Summary of consensus recommendations for bronchiectasis and chronic suppurative lung disease (CSLD)
CF = cystic fibrosis. c-HRCT = chest high-resolution computed tomography. NHMRC = National Health and Medical Research Council. ◆
1a. CSLD describes respiratory symptoms and signs (Box 4) in children 
without radiographic features of bronchiectasis.
1b. Chest HRCT scans are needed to confirm bronchiectasis as a 
diagnosis.
2. Patients with symptoms or signs of bronchiectasis need a c-HRCT scan 
to confirm the diagnosis and to assess the severity and extent of disease. 
Specialist advice is required before ordering scans for children.
3. Perform baseline investigations. These include:
? Culturing airway secretion;
? Spirometry (when aged > 6 years);
? Immune function tests (Box 4);
? Bronchoscopy (for foreign body, airway abnormality and 
microbiological culture);
? Echocardiogram in adults (on specialist recommendation in children); 
and
? Other investigations (eg, sweat test, tests for tuberculosis, barium 
swallow) may be necessary in selected patients.
4. Intensive medical therapy optimises general wellbeing, symptom 
control, lung function and quality of life, as well as reducing exacerbation 
frequency.
5. Antibiotics (Box 5) are based on lower airway microbiology (sputum or 
bronchoalveolar lavage), local antibiotic susceptibility patterns and 
clinical severity.
6. In patients not needing hospitalisation for an acute exacerbation, oral 
antibiotics are prescribed for at least 10–14 days.
7. Patients failing to respond to oral antibiotics for an acute exacerba-tion 
are hospitalised for more intensive treatment, including intravenous 
antibiotics. This usually requires hospitalisation for at least 7 days.
8. Inhaled and oral corticosteroids should not be routinely 
prescribed and only used on an individual basis.
9. Inhaled bronchodilators should not be routinely prescribed and 
only used on an individual basis.
10. Recombinant human deoxyribonuclease is contraindicated in 
non-CF bronchiectasis.
11. At present, other mucoactive agents are not routinely 
recommended.
12. Airway clearance manoeuvres are recommended, and 
physiotherapists’ advice should be sought. The technique and 
frequency of chest physiotherapy is individualised.
13. Adults with bronchiectasis and limited exercise tolerance should 
receive pulmonary rehabilitation.
14. Assess and optimise children’s nutrition.
15. Promote smoking elimination, including second-hand smoke 
exposure.
16. Avoid biomass smoke exposure.
17. Regularly monitor for complications and comorbidities (Box 6). 
When present, these are managed following standard therapies 
and guidelines.
18. Ensure timely annual influenza immunisation and that 
pneumococcal vaccines are administered according to NHMRC and 
local guidelines.
19. Comprehensive health service delivery systems are essential for 
managing chronic conditions in rural and remote regions. 
Management guidelines, clear referral systems and links with 
specialists will strengthen the capacity of health services to deliver 
high-quality care.MJA • Volume 189 Number 7 • 6 October 2008 389
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ing regular antibiotics and physiotherapy.26
Antibiotics
We recommend treating severe or persistent exacerbations of
bronchiectasis with intravenous antibiotics and physiotherapy in
hospital. Short antibiotic courses of 10–14 days reduce symptoms
and levels of inflammatory markers and improve quality of life.8 In
contrast, maintaining antibiotic treatment for as long as 12 months
confers only a small benefit.27 Nonetheless, prolonged courses of
macrolide antibiotics are being used.14 Azithromycin treatment for
6–36 months in patients with CF initially improves lung function
and quality-of-life scores while reducing exacerbation frequency.
However, these benefits are not sustained, and development of
antibiotic resistance is a matter of concern.28,29 Studies of mac-
rolide use in patients with non-CF bronchiectasis are limited.14
Adults receiving twice-weekly azithromycin for 6 months have
been shown to have reduced respiratory exacerbations and sputum
volume.13 However, until longer-term trials are conducted, mac-
rolides cannot be routinely recommended.
Ideally, antibiotics should be prescribed according to sputum
culture and susceptibility results. Young children cannot usually
expectorate sputum and, if a child is seriously ill or unresponsive
to empirical antibiotics, a lower airway specimen can be collected
by bronchoalveolar lavage. Adults with severe disease should
initially receive antipseudomonal antibiotic therapy if cultures are
unavailable.
Recommendation 4
Intensive medical therapy optimises general wellbeing, symp-
tom control, lung function and quality of life, as well as
reducing exacerbation frequency.
Agreement level: A+, 100%
Grade: high; evidence level: cohort studies, Cochrane reviews,
randomised controlled trials (RCTs)
Recommendation 5
Antibiotics (Box 5) are based on lower airway microbiology
(sputum or bronchoalveolar lavage), local antibiotic suscept-
ibility patterns and clinical severity.
Agreement level: A+, 86%; A, 14%
Grade: moderate; evidence level: cohort studies
Recommendation 6
In patients not needing hospitalisation for an acute exacerba-
tion, oral antibiotics are prescribed for at least 10–14 days.
Agreement level: A+, 89%; A, 8%; D, 3%
Grade: low; evidence level: cohort studies
Recommendation 7
Patients failing to respond to oral antibiotics for an acute
exacerbation are hospitalised for more intensive treatment,
including intravenous antibiotics. This usually requires
hospitalisation for at least 7 days.
Agreement level: A+, 89%; A, 8%; D, 3%
Grade: low; evidence level: cohort studies
Corticosteroids, bronchodilators and mucolytics
When asthma-like symptoms exist, lung function deterioration is
accelerated.6 Patients with either bronchodilator or airway hyper-
responsiveness should receive β2-agonists and inhaled corticoster-
oids. But reviews have found insufficient evidence to recommend
their routine use.14,15 The trials involved small numbers of subjects
and post-hoc subgroup analyses of doubtful validity. Although
sputum volume was reduced in patients receiving inhaled cortico-
steroids, this required high doses, which were associated with
adverse long-term complications.
At present there is insufficient evidence to recommend muco-
lytics (such as mannitol or hypertonic saline) as routine treatment.
Recombinant deoxyribonuclease, although effective in patients
with CF, is harmful to adults with bronchiectasis, as it is associated
with higher exacerbation and hospitalisation rates and a more
rapid decline in lung function.31
Recommendation 8
Inhaled and oral corticosteroids should not be routinely pre-
scribed and only used on an individual basis.
Agreement level: A+, 95%; A, 2.5%; A–, 2.5%
Grade: low; evidence level: Cochrane reviews, RCTs
Recommendation 9
Inhaled bronchodilators should not be routinely prescribed and
only used on an individual basis.
Agreement level: A+, 92%; A, 8%
Grade: low; evidence level: Cochrane reviews
4 Bronchiectasis: symptoms and signs, associated 
conditions and tests
Symptoms and signs of bronchiectasis
Excessively prolonged (> 12 weeks) wet cough, exertional dyspnoea, 
asthma-like symptoms and recurrent chest infections. Clinical signs, 
which are often delayed, include growth failure, digital clubbing, chest 
wall deformity, hyperinflation, and adventitial sounds on chest 
auscultation.3 In advanced disease, chronic hypoxaemia and signs of 
pulmonary hypertension may be present. In children, triggers for 
referral to a specialist include more than two episodes (> 4 weeks) of 
chronic wet cough per year responding to antibiotics, and persistent 
chest radiographic abnormality. As cough is commonly under-
reported by Indigenous people, it is useful to obtain additional 
medical information from the local community (eg, clinic staff, carers, 
health workers, clinic notes) about the nature and duration of cough.4
Possible aetiologies in bronchiectasis
Congenital diseases (eg, cystic fibrosis, primary ciliary dyskinesia, 
α1-antitrypsin deficiency, tracheobronchomegaly, bronchomalacia); 
immunodeficiency (eg, associated with hypo-γ -globulinaemia, 
neutrophil function abnormalities, HIV infection); aspiration 
(including foreign body); chronic infections (eg, tuberculosis, 
aspergillosis, non-tuberculous mycobacterial infections); chronic 
obstructive pulmonary disease; bronchiolitis obliterans; and 
systemic (eg, autoimmune) disorders.
Recommended blood tests at baseline
Basic immune function assessment: full blood count, including 
differential white blood cell count; HIV testing (in adults and at-risk 
children); levels of IgG (+ subclasses), IgA, IgM, and IgE; and 
antibody responses to vaccine protein and polysaccharide antigens. 
In selected situations, other investigations may be necessary (eg, 
neutrophil function studies and lymphocyte subsets). In Central 
Australia, HTLV-1 serology should also be included. ◆390 MJA • Volume 189 Number 7 • 6 October 2008
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Recombinant human deoxyribonuclease is contraindicated in
non-CF bronchiectasis.
Agreement level: A+, 95%; A, 5%
Grade: low; evidence level: Cochrane reviews
Recommendation 11
At present, other mucoactive agents are not routinely recom-
mended.
Agreement level: A+, 86%; A, 14%
Grade: low; evidence level: Cochrane reviews
Airway clearance
Chest physiotherapy is standard treatment in CF and improves
airway clearance.8 There has been little research on the effect of
physiotherapy in patients with non-CF bronchiectasis. Positive
expiratory pressure techniques are commonly used in children.
Head-down tilt is avoided because it increases gastro-oesophageal
reflux and possible aspiration.32 Various physiotherapy techniques
with varying benefits have been employed.33
Recommendation 12
Airway clearance manoeuvres are recommended, and physio-
therapists’ advice should be sought. The technique and fre-
quency of chest physiotherapy is individualised.
Agreement level: A+, 97%; A, 3%
Grade: moderate; evidence level: Cochrane review (no RCT),
RCTs (for physiotherapy techniques)
Recommendation 13
Adults with bronchiectasis and limited exercise tolerance
should receive pulmonary rehabilitation.
Agreement level: A+, 86%; A, 8%; A–, 3%; D, 3%
Grade: moderate; evidence level: Cochrane review
Nutrition
Evidence from patients with CF suggests that poor nutrition is a
risk factor for respiratory decline. Nutritional status may have a
greater impact on CSLD and bronchiectasis in a child with
developing lungs than in an adult.
Recommendation 14
Assess and optimise children’s nutrition.
Agreement level: A+, 97%; A–, 3%
Grade: moderate; evidence level: extrapolated from cohort
studies on chronic lung disease
Minimising further lung injury
Environmental pollutants, including tobacco and indoor wood-
smoke, exacerbate chronic respiratory illnesses by increasing the
risk of acute respiratory infection.4 Efforts to reduce childhood
smoke exposure, in utero and in the home environment, must be
maximised.
Recommendation 15
Promote smoking elimination, including second-hand smoke
exposure.
Agreement level: A+, 100%
Grade: high; evidence level: extrapolated from cohort studies
on chronic lung disease
Recommendation 16
Avoid biomass smoke exposure.
Agreement level: A+, 97%; A, 3%
Grade: low; evidence level: extrapolated from cohort studies
on respiratory infection
Monitoring, comorbidities and prevention of acute 
exacerbations
Patients with bronchiectasis have increased incidence of co-
morbidities.8 Attention to oral hygiene is necessary, as dental caries
are associated with pulmonary disease severity.8 In adults, bron-
chiectasis may coexist with COPD (in 29%–50% of patients) and is
frequently undiagnosed.8,34
Although published data are limited, a coordinated management
approach may reduce bronchiectasis mortality and complication
5 Recommended antibiotics for patients with bronchiectasis or chronic suppurative lung disease
Mild–moderate exacerbation (oral therapy) Severe exacerbation (intravenous therapy)
Initial empirical therapy* Amoxycillin or doxycycline† Children: cefotaxime or ceftriaxone; adults: ticarcillin–clavulanate
Organism-specific therapy
Haemophilus influenzae Amoxycillin Ampicillin
β-Lactamase-positive organisms Amoxycillin–clavulanate or doxycycline† Cefotaxime or ceftriaxone
Streptococcus pneumoniae Amoxycillin Benzylpenicillin G
Moraxella catarrhalis Amoxycillin–clavulanate Cefotaxime or ceftriaxone
Staphylococcus aureus Flucloxacillin or cephalexin Flucloxacillin
Pseudomonas aeruginosa Ciprofloxacin Children: ticarcillin–clavulanate + tobramycin;‡ adults: ticarcillin–
clavulanate
Methicillin-resistant S. aureus and 
non-tuberculous mycobacteria
Seek specialist advice Seek specialist advice
* Initial treatment is determined by the most recent culture results, but if these are unavailable and the patient is a child, treat for H. influenzae, taking into account local 
resistance patterns. If the patient is an adult and seriously ill, treat for P. aeruginosa until culture results are available. † Doxycycline is used only in adults and children 
aged over 8 years. ‡ Tobramycin is only appropriate in situations in which drug level and renal function can be closely monitored. Inhaled tobramycin is promising, but 
there is currently insufficient evidence for its routine use in patients with non-cystic fibrosis bronchiectasis.30 ◆MJA • Volume 189 Number 7 • 6 October 2008 391
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health care, specialist reviews and intensive therapy to reduce
exacerbation frequency and severity and to slow pulmonary
decline.26,35
Recommendation 17
Regularly monitor for complications and comorbidities (Box 6).
When present, these are managed following standard therapies
and guidelines.
Agreement level: A+, 95%; A, 5%
Grade: moderate; evidence level: cohort studies
Public health issues, prevention and appropriate health 
care delivery
Breastfeeding helps protect children from CSLD and bronchiectasis.23
All Indigenous children and adults should receive the routine vaccin-
ations outlined in The Australian immunisation handbook,36 including
annual influenza and pneumococcal vaccines. These and other
important public health measures are beyond the scope of our article.
In brief, health is closely linked to socioeconomic factors, and
increased poverty is an independent risk factor for acute respiratory
infection.4 Successful management and prevention of bronchiectasis
in Indigenous people will only be achieved by delivering comprehen-
sive health care accompanied by improvements in housing, education
and employment and reduction in poverty levels.
Effective delivery of treatment and disease control programs
requires a comprehensive primary health care service. Greater
efforts are needed to educate all health care providers in the
following areas:
• Identifying and referring children and adults with suspected
CSLD or bronchiectasis; and
• Enhancing the role of health care providers in primary manage-
ment of these disorders.
Delivering optimal health care in a setting of entrenched poverty
and major social disadvantage is difficult. However, the definite
benefits of optimal care should not be underestimated. The chal-
lenge for health service systems is to find ways to deliver effective,
quality health care despite problems such as remoteness, endemic
poverty, educational disadvantage, dysfunctional communities, and
comorbidities in children, their carers and adults. Priority areas for
health delivery and research are outlined in Box 7.
Recommendation 18
Ensure timely annual influenza immunisation and that pneu-
mococcal vaccines are administered according to National
Health and Medical Research Council (NHMRC) and local
guidelines.
Agreement level: A+, 97%; A, 3%
Grade: low for pneumococcal vaccine, moderate for influenza
vaccine; evidence level: Cochrane review (no RCT)
Recommendation 19
Comprehensive health service delivery systems are essential for
managing chronic conditions in rural and remote regions.
Management guidelines, clear referral systems and links with
specialists will strengthen the capacity of health services to
deliver high-quality care.
Agreement level: A+, 100%
Grade: not applicable
6 Regular review for complications and comorbidities in 
patients with bronchiectasis or chronic suppurative 
lung disease
Adults should be reviewed every year and children every 6 months. 
A multidisciplinary team is recommended, especially when 
providing initial education. The review should include:
• Assessment of severity, including an assessment of exacerbation 
frequency, exercise tolerance, signs of right heart failure, pulse 
oximetry and spirometry. Patients with suspected right heart 
failure or hypoxia should be referred early.
• Identifying and managing bronchiectasis complications and 
comorbidities, particularly gastro-oesophageal reflux, reactive 
airway disease, asthma and chronic obstructive pulmonary 
disease. Occasionally, patients require assessments for sleep-
disordered breathing and cardiac complications. ◆
7 Priority areas for chronic suppurative lung disease 
(CSLD) and bronchiectasis in Indigenous Australians 
living in rural and remote areas
Research
• Accurate assessment of disease burden.
• Increased understanding of natural history of CSLD and 
bronchiectasis.
• Evaluation of interventions to:
? prevent progression of CSLD to established bronchiectasis in 
children;
? reduce frequency and severity of acute exacerbations, 
including delaying progress of bronchiectasis to uninvolved 
lung (via antibiotics, mucoactive agents, multidisciplinary 
care); and
? improve effectiveness of airway clearance techniques and 
pulmonary rehabilitation.
Service delivery
• Use of spirometry in primary health care, including training and 
support of staff in supervising and interpreting spirometry.
• Patient access, staff and equipment to perform c-HRCT scans to 
diagnose bronchiectasis and to conduct bronchoscopy for 
baseline assessment.
• Training of primary health care doctors, nurses, allied health 
workers, Indigenous health workers, paediatricians and 
physicians in diagnosis, management and patient and carer 
education with regard to CSLD in children and bronchiectasis in 
both adults and children.
• Access to advice and review by paediatric and adult specialist 
respiratory services.
• Development of pulmonary rehabilitation programs for adults 
with bronchiectasis.
• Well defined systems for early identification and referral of 
patients who may benefit from lung transplantation.
• Development of multidisciplinary teams, particularly including 
physiotherapists, to help patients and carers in the ongoing 
management of CSLD and bronchiectasis. Teams should:
? support primary health care providers;
? help with hospitalised patient care; and
? liaise between primary health care and hospital services to 
optimise ambulatory and inpatient management.
c-HRCT = chest high-resolution computed tomography. ◆392 MJA • Volume 189 Number 7 • 6 October 2008
POSITIO N STATEMENTAcknowledgements
We thank Bilawara Lee, a senior member of the Larrakia Nation, who opened
the workshop and welcomed us to her country, where the workshop took
place. Anne Chang is supported by the Royal Children’s Hospital Foundation
and by an NHMRC Practitioner Fellowship.
Competing interests
Keith Grimwood was previously a member of a Rotavirus Advisory Board in
New Zealand and received a research grant from GlaxoSmithKline to study
the epidemiology of intussusception in New Zealand. He has also received a
research grant from Merck for a rotavirus surveillance study and is currently
chair of a Data and Safety Monitoring Committee for phase I and II trials of a
meningococcal vaccine for Wyeth. Graeme Maguire receives research fund-
ing from the NHMRC, the Office for Aboriginal and Torres Strait Islander
Health and the Cooperative Research Centre for Aboriginal Health to
facilitate the conduct of research projects on Indigenous Australian respira-
tory health and disease.
Author details
Anne B Chang, MPHTM, PhD, FRACP, Paediatric Respiratory Physician,1 
and Head2
Keith Grimwood, MB ChB, FRACP, MD, Paediatric Infectious Diseases 
Physician,3 and Director of Research, Royal Children’s Hospital4
Graeme Maguire, MB BS, FRACP, Associate Professor5
Paul T King, MB BS, FRACP, PhD, Staff Specialist in Respiratory 
Medicine6
Peter S Morris, MB BS, FRACP, PhD, Deputy Head,2 and Associate 
Professor of Child Health7
Paul J Torzillo, MB BS, FRACP, Medical Director,8 and Senior 
Respiratory Physician9
1 Department of Respiratory Medicine, Royal Children’s Hospital, 
Brisbane, QLD.
2 Child Health Division, Menzies School of Health Research, Charles 
Darwin University, Darwin, NT.
3 Queensland Paediatric Infectious Diseases Laboratory, Royal 
Children’s Hospital, Brisbane, QLD.
4 Discipline of Paediatrics and Child Health, University of Queensland, 
Brisbane, QLD.
5 School of Medicine, James Cook University, Cairns, QLD.
6 Department of Medicine and Department of Respiratory Medicine, 
Monash Medical Centre, Melbourne, VIC.
7 Northern Territory Clinical School, Flinders University, Darwin, NT.
8 Nganampa Health Council, Alice Springs, NT.
9 Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW.
Correspondence: annechang@ausdoctors.net
References
1 Standing Committee on Aboriginal and Torres Strait Islander Health and
Statistical Information Management Committee 2006. National summary of
the 2003 and 2004 jurisdictional reports against the Aboriginal and Torres
Strait Islander health performance indicators. Canberra: AIHW, 2006. (AIHW
Cat. No. IHW 16.) http://www.aihw.gov.au/publications/index.cfm/title/
10234 (accessed Jul 2008).
2 Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander
Health Survey, 2004–05. Canberra: ABS, 2006. (ABS Cat. No. 4715.0.)
3 Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis: clinical and
HRCT evaluation. Pediatr Pulmonol 2003; 35: 477-483.
4 Chang AB, Grimwood K, Mulholland EK, Torzillo PJ; Working Group on
Indigenous Paediatric Respiratory Health. Bronchiectasis in Indigenous chil-
dren in remote Australian communities. Med J Aust 2002; 177: 200-204. 
5 King PT, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis.
COPD 2005; 2: 27-34.
6 Keistinen T, Säynäjäkangas O, Tuuponen T, Kivelä SL. Bronchiectasis: an
orphan disease with a poorly-understood prognosis. Eur Respir J 1997; 10:
2784-2787.
7 Steinfort DP, Brady S, Weisinger HS, Einsiedel L. Bronchiectasis in Central
Australia: a young face to an old disease. Respir Med 2008; 102: 574-578.
8 Chang AB, Bilton D. Non-cystic fibrosis bronchiectasis exacerbations. Thorax
2008; 63: 269-276.
9 Kiechl S, Egger G, Mayr M, et al. Chronic Infections and the risk of carotid
atherosclerosis: prospective results from a large population study. Circulation
2001; 103: 1064-1070.
10 Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of
patients with bronchiectasis to treatment with amoxycillin given in standard
or high doses orally or by inhalation. Thorax 1986; 41: 559-565.
11 Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of
recommendations. BMJ 2004; 328: 1490-1497.
12 Vakil N, van Zanten SV, Kahrilas P, et al; Global Consensus Group. The
Montreal definition and classification of gastroesophageal reflux disease: a
global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920.
13 Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects
of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir
Med 2005; 4: 117-122.
14 King P. Is there a role for inhaled corticosteroids and macrolide therapy in
bronchiectasis? Drugs 2007; 67: 965-974.
15 Chang AB, Redding GJ, Everard ML. Chronic wet cough: protracted bronchi-
tis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol
2008; 43: 519-531.
16 Webb WR, Müller NL, Naidich DP. High-resolution CT of the lung. Philadel-
phia: Lippincott, Williams & Wilkins, 2001: 467-546.
17 Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial
wall thickness on high-resolution CT in asymptomatic subjects: correlation
with age and smoking. AJR Am J Roentgenol 2003; 180: 513-518.
18 Chang AB, Masel JP, Boyce NC, Torzillo PJ. Respiratory morbidity in central
Australian Aboriginal children with alveolar lobar abnormalities. Med J Aust
2003; 178: 490-494. 
19 Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with
bronchiectasis. Respir Med 2007; 101: 1163-1170.
20 King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and
presenting clinical features of adult bronchiectasis. Respir Med 2006; 100:
2183-2189.
21 Croxatto OC, Lanari A. Pathogenesis of bronchiectasis; experimental study
and anatomic findings. J Thorac Surg 1954; 27: 514-528.
22 Stockley RA. Role of bacteria in the pathogenesis and progression of acute
and chronic lung infection. Thorax 1998; 53: 58-62.
23 Valery PC, Torzillo PJ, Mulholland EK, et al. Hospital-based case–control
study of bronchiectasis in Indigenous children in Central Australia. Pediatr
Infect Dis J 2004; 23: 902-908.
24 Judson MA. Noninvasive Aspergillus pulmonary disease. Semin Respir Crit
Care Med 2004; 25: 203-219.
25 Chan CH, Ho AK, Chan RC, et al. Mycobacteria as a cause of infective
exacerbation in bronchiectasis. Postgrad Med J 1992; 68: 896-899.
26 Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of
primary ciliary dyskinesia. Eur Respir J 1997; 10: 2376-2379.
27 Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bron-
chiectasis. Cochrane Database Syst Rev 2007; (2): CD001392.
28 Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis.
Cochrane Database Syst Rev 2004; (2): CD002203.
29 Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin
treatment in pediatric patients with cystic fibrosis: long-term outcomes
related to macrolide resistance and pulmonary function. Pediatr Infect Dis J
2007; 26: 8-12.
30 Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis.
J Aerosol Med 2008; Feb 7 [Epub ahead of print].
31 O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic
bronchiectasis with aerosolized recombinant human DNase I. rhDNase
Study Group. Chest 1998; 113: 1329-1334.
32 Button BM, Heine RG, Catto-Smith AG, Phelan PD. Postural drainage in
cystic fibrosis: is there a link with gastro-oesophageal reflux? J Paediatr Child
Health 1998; 34: 330-334.
33 Patterson JE, Bradley JM, Elborn JS. Airway clearance in bronchiectasis: a
randomized crossover trial of active cycle of breathing techniques (incorpor-
ating postural drainage and vibration) versus test of incremental respiratory
endurance. Chron Respir Dis 2004; 1: 127-130.
34 O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological
characterisation of patients diagnosed with chronic obstructive pulmonary
disease in primary care. Thorax 2000; 55: 635-642.
35 Karadag B, Karakoc F, Ersu R, et al. Non-cystic-fibrosis bronchiectasis in
children: a persisting problem in developing countries. Respiration 2005; 72:
233-238.
36 National Health and Medical Research Council. The Australian immunisation
handbook. 9th ed. Canberra: NHMRC, 2008.
(Received 26 Dec 2007, accepted 23 Apr 2008) ❏MJA • Volume 189 Number 7 • 6 October 2008 393
